AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS - 2020 Issue 3; Ask the Editor
Refusal of Adjuvant Therapy for Breast Carcinoma Status Post Mastectomy
A patient, who was diagnosed with an infiltrating ductal carcinoma of the right breast of overlapping sites, presents for an outpatient follow-up visit after previously undergoing an excisional lumpectomy with sentinel lymph node dissection. Margins on the pathology report were clear and the sentinel lymph node was benign. During the follow-up visit, the oncologist recommended adjuvant endocrine therapy. However, the patient refused adjuvant therapy because her primary care physician indicated the benefits would be minimal. What is the appropriate code assignment for this visit since the patient is without evidence of any remaining cancer and is refusing adjuvant endocrine therapy? ...
Subscribe or sign in to view the full article.
Article Overview
This article explains the coding considerations for a follow-up visit after completed breast cancer treatment in a patient who has no evidence of residual disease and is refusing recommended adjuvant endocrine therapy. It is relevant to coders, billers, and oncology practices that need to distinguish post-treatment surveillance visits from active cancer care and understand the diagnosis coding context for refusal of additional therapy. The discussion is centered on a breast oncology scenario and the broader follow-up coding framework used in this setting.
Why This Topic Matters
Accurate coding for post-treatment oncology follow-up affects problem list accuracy, visit classification, and how the patient’s cancer history and current status are represented in the medical record and claims.
What You Will Learn
- How follow-up visits are categorized after completion of malignant neoplasm treatment
- How a refusal of recommended adjuvant therapy fits into the follow-up coding context
- How the article frames diagnosis coding for a breast cancer surveillance encounter without residual disease
- How to interpret the encounter setting and treatment status in an oncology follow-up scenario
Who Should Read This
- Medical coders
- Coding auditors
- Oncology billers
- Health information management professionals
- Physician practice staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com